1. Home
  2. DLPN vs SGMT Comparison

DLPN vs SGMT Comparison

Compare DLPN & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DLPN
  • SGMT
  • Stock Information
  • Founded
  • DLPN 1996
  • SGMT 2006
  • Country
  • DLPN United States
  • SGMT United States
  • Employees
  • DLPN N/A
  • SGMT N/A
  • Industry
  • DLPN Other Consumer Services
  • SGMT
  • Sector
  • DLPN Consumer Discretionary
  • SGMT
  • Exchange
  • DLPN Nasdaq
  • SGMT Nasdaq
  • Market Cap
  • DLPN 11.4M
  • SGMT 71.2M
  • IPO Year
  • DLPN N/A
  • SGMT 2023
  • Fundamental
  • Price
  • DLPN $1.05
  • SGMT $3.30
  • Analyst Decision
  • DLPN Strong Buy
  • SGMT Strong Buy
  • Analyst Count
  • DLPN 1
  • SGMT 6
  • Target Price
  • DLPN $5.00
  • SGMT $25.67
  • AVG Volume (30 Days)
  • DLPN 13.8K
  • SGMT 553.0K
  • Earning Date
  • DLPN 05-13-2025
  • SGMT 05-08-2025
  • Dividend Yield
  • DLPN N/A
  • SGMT N/A
  • EPS Growth
  • DLPN N/A
  • SGMT N/A
  • EPS
  • DLPN N/A
  • SGMT N/A
  • Revenue
  • DLPN $51,684,984.00
  • SGMT N/A
  • Revenue This Year
  • DLPN $2.62
  • SGMT N/A
  • Revenue Next Year
  • DLPN $22.65
  • SGMT N/A
  • P/E Ratio
  • DLPN N/A
  • SGMT N/A
  • Revenue Growth
  • DLPN 19.86
  • SGMT N/A
  • 52 Week Low
  • DLPN $0.75
  • SGMT $1.73
  • 52 Week High
  • DLPN $2.78
  • SGMT $7.38
  • Technical
  • Relative Strength Index (RSI)
  • DLPN 53.50
  • SGMT 53.97
  • Support Level
  • DLPN $1.00
  • SGMT $3.19
  • Resistance Level
  • DLPN $1.16
  • SGMT $3.45
  • Average True Range (ATR)
  • DLPN 0.06
  • SGMT 0.31
  • MACD
  • DLPN 0.00
  • SGMT 0.05
  • Stochastic Oscillator
  • DLPN 55.56
  • SGMT 55.52

About DLPN Dolphin Entertainment Inc.

Dolphin Entertainment Inc is an independent entertainment marketing and production company. It provides strategic marketing and publicity services to many of the top brands, both individual and corporate, in the motion picture, television, music, gaming, culinary, hospitality, and lifestyle industries. It operates in two reportable segments: Entertainment publicity and marketing and Content production. It generates the majority of its revenue from the Entertainment publicity and marketing segment which provides clients with diversified marketing services, including public relations, entertainment and hospitality content marketing, strategic marketing consulting, and content production of marketing materials.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: